These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11797509)

  • 1. [Kinetics and dosimetry of monoclonal antibody MAb-170: evaluation of possibilities for intraperitoneal radioimmunotherapy].
    Alexander C; Holländer M; Schmidt W; Kirsch CM
    Nuklearmedizin; 2001 Dec; 40(6):207-14. PubMed ID: 11797509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
    Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
    Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
    Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration.
    Buijs WC; Tibben JG; Boerman OC; Molthoff CF; Massuger LF; Koenders EB; Schijf CP; Siegel JA; Corstens FH
    Eur J Nucl Med; 1998 Nov; 25(11):1552-61. PubMed ID: 9799353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.
    Antonescu C; Bischof Delaloye A; Kosinski M; Monnin P; Schaffland AO; Ketterer N; Grannavel C; Kovacsovics T; Verdun FR; Buchegger F
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):943-51. PubMed ID: 15824926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
    Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.